SUMMIT
2025
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
In 731 patients with HFpEF and obesity, tirzepatide reduced cardiovascular death or worsening heart failure compared with placebo.
Result
Efficacy: CV death or worsening HF event; KCCQ score (co-primary)HR 0.62
Below 1 favours tirzepatide, above 1 favours placebo.
Also reported: KCCQ improved by ~ 6.9 points.
- Subtopic
- Obesity & HFpEF
- Design
- Double-blind RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2026 HFACC/AHA 2026 CKM
- Source
- Packer M, et al. N Engl J Med. 2025;392(5):427-437.doi 10.1056/NEJMoa2410027
Discussion & critique
Targets the obesity phenotype of HFpEF directly. Small and event-light: the symptom (KCCQ) benefit is more robust than the hard-outcome composite.